On March 12, 2026, the Manitoba Health Coalition and Ontario Health Coalition announced that two donors had died at for‑profit plasma collection facilities owned by Grifols in Canada. The deaths actually occurred in October 2025 and January 2026, but the press conference and media reports were issued on March 12, 2026, making the announcement a new event.
Grifols issued a statement saying it had “no reason to believe that there is a correlation between the donors’ passing and plasma donation.” The company reiterated that its centers are licensed and regulated by the FDA and other international agencies, and that donor health and safety remain a top priority. It also highlighted its internal regulatory program designed to maintain compliance.
Health Canada has opened an investigation into the incidents, following earlier inspections that uncovered non‑compliant ratings for record‑keeping, donor screening, and equipment maintenance at Grifols’ Canadian facilities. The investigation comes amid a broader context of blood‑safety concerns in Canada, where past scandals have heightened scrutiny of for‑profit plasma collection.
Financially, Grifols reported 2025 revenue of €7,524 million and a net profit of €402 million, more than doubling the previous year’s profit. For 2026, the company is targeting adjusted EBITDA growth of 5‑9% and an adjusted EBITDA margin of at least 25%. While the fatality incident has not yet produced a direct financial hit, the heightened regulatory scrutiny could affect investor confidence and operational costs.
The incident may lead to increased regulatory oversight and potential legal challenges, adding headwinds to Grifols’ already complex operating environment. Management has faced criticism from short‑seller Gotham City Research over alleged profit overstating, and the current safety concerns could compound reputational risks. Investors and regulators will likely monitor how Grifols addresses the investigation and whether it implements additional safety measures to restore confidence.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.